Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.

NCT Number	NCT04093167
Lead Sponsor	Canadian Cancer Trials Group Collaborators: Cancer Research Institute, New York City, Personal Genome Diagnostics, Mark Foundation for Cancer Research
Conditions	Lung Cancer
Enrollment	53 participants
Start Date	2020-05-26
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-31